title: Central IL-1 receptor signaling regulates bone growth and mass.
abstract: The proinflammatory cytokine IL-1, acting via the hypothalamic IL-1 receptor type 1 (IL-1RI), activates pathways known to suppress bone formation such as the hypothalamo pituitary-adrenocortical axis and the sympathetic nervous system. In addition, peripheral IL-1 has been implicated as a mediator of the bone loss induced by sex hormone depletion and TNF. Here, we report an unexpected low bone mass (LBM) phenotype, including impairment of bone growth, in IL-1RI-deficient mice (IL-1rKO mice). Targeted overexpression of human IL-1 receptor antagonist to the central nervous system using the murine glial fibrillary acidic protein promoter (IL-1raTG mice) resulted in a similar phenotype, implying that central IL-1RI silencing is the causative process in the LBM induction. Analysis of bone remodeling indicates that the process leading to the LBM in both IL-1rKO and IL-1raTG is characterized mainly by doubling the osteoclast number. Either genetic modification does not decrease testosterone or increase corticosterone serum levels, suggesting that systems other than the gonads and hypothalamo pituitary-adrenocortical axis mediate the central IL-1RI effect on bone. We further demonstrate that WT mice express mouse IL-1ra in bone but not in the hypothalamus. Because low levels of IL-1 are present in both tissues, it is suggested that skeletal IL-1 activity is normally suppressed, whereas central IL-1 produces a constant physiologic stimulation of IL-1RI signaling. Although the pathway connecting the central IL-1RI signaling to bone remodeling remains unknown, the outburst of osteoclastogenesis in its absence suggests that normally it controls bone growth and mass by tonically restraining bone resorption.
authors.affiliation: Bone Laboratory, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
authors.forename: Alon
authors.initials: A
authors.lastname: Bajayo
authors.forename: Inbal
authors.initials: I
authors.lastname: Goshen
authors.forename: Sharon
authors.initials: S
authors.lastname: Feldman
authors.forename: Valer
authors.initials: V
authors.lastname: Csernus
authors.forename: Kerstin
authors.initials: K
authors.lastname: Iverfeldt
authors.forename: Esther
authors.initials: E
authors.lastname: Shohami
authors.forename: Raz
authors.initials: R
authors.lastname: Yirmiya
authors.forename: Itai
authors.initials: I
authors.lastname: Bab
mesh_terms: D000818:Animals; D015519:Bone Density / Q000502:physiology*; D001846:Bone Development / Q000502:physiology*; D001862:Bone Resorption; D005904:Glial Fibrillary Acidic Protein / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009929:Organ Size; D010641:Phenotype; D010913:Pituitary-Adrenal System / Q000378:metabolism; D017472:Receptors, Interleukin-1 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D013256:Steroids / Q000097:blood
chemical_list: D005904:Glial Fibrillary Acidic Protein; D017472:Receptors, Interleukin-1; D013256:Steroids